Catheter Precision Completes Full Acquisition of Aviation Platform Flyte

Catheter Precision completes its acquisition of AI aviation service Flyte Inc., transitioning to a 100% owned subsidiary to target the on-demand regional air travel market.

Catheter Precision has solidified its strategic pivot from a medical device specialist to a diversified technology holding company. The firm has announced the completion of its acquisition of Flyte Inc., marking a decisive entry into the regional air mobility sector. This move transitions what began as a strategic minority stake into full ownership of the AI-powered aviation service provider.

A Two-Phase Acquisition Strategy

The transaction to gain full control was executed in two distinct phases. An initial investment in February 2026 secured Catheter Precision a 19.98% stake in Flyte. The company has now finalized the purchase of the remaining shares from Creatd Inc., which also included the Ponderosa unit. The total consideration for Flyte and Ponderosa amounted to $11.55 million.

With this deal closed, Catheter Precision now commands the complete operational framework and booking platform of the business, previously known under the name Flewber Global. Flyte’s status has been transformed from a financial investment into a wholly-owned, fully integrated subsidiary. Company leadership anticipates this will allow for direct participation in the value chain of the on-demand aviation market.

Targeting Regional Travel Efficiency

The core of Flyte’s business model addresses a specific niche in short-haul transportation. By utilizing smaller regional airports, the service bypasses ground traffic congestion and the lengthy processing times typical of major airline hubs. Its fleet is centered on Cirrus Vision Jets, which operate under an FAA Part 135 certification for on-demand charter flights. This approach blends regional business travel with private charter flexibility.

For investors monitoring the integration and growth trajectory, several key operational and financial details are now in focus:

• Fleet Composition: Reliance on Cirrus Vision Jets for regional short-haul routes.
• Regulatory Framework: Operations are conducted under strict FAA 14 CFR Part 135 regulations.
• Transaction Value: The complete acquisition required a total investment of $11.55 million.
• Ownership Shift: Stake increased from 19.98% to 100% ownership.

The full consolidation is expected to unlock operational synergies and enhance cash flow stability within the capital-intensive aviation industry. A primary growth driver is the scaling of Flyte's AI platform, designed to efficiently connect travelers across regional corridors.

Comprehensive details regarding the consolidated balance sheet and the operational performance of the new aviation segment will be disclosed in Catheter Precision’s forthcoming periodic financial reports. In the interim, the utilization rate of the jet fleet will serve as a critical indicator of the success of the restructured corporation.